OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Seymour on the Design of the ELEVATE-RR Trial in Relapsed/Refractory CLL

December 21st 2021

John F. Seymour, MBBS, FRACP, PhD, discusses the design of the phase 3 ELEVATE-RR trial comparing acalabrutinib vs ibrutinib in chronic lymphocytic leukemia.

Dr. Jain on the Importance of Communication for Multidisciplinary Care in CRC

December 21st 2021

Shikha Jain, MD, FACP, discusses the importance of communication in patients with colorectal cancer and liver metastases who are receiving multidisciplinary care.

Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL

December 21st 2021

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.

Dr. Kremyanskaya on the Design of the MANIFEST Trial in Myelofibrosis

December 21st 2021

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Dr. Shirasu on the Clinical Implications of ctDNA in CRC

December 20th 2021

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Dr. Gomella on Novel Biomarker Research in Prostate Cancer

December 20th 2021

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

Dr. Zurita-Saavedra on Leveraging Antiandrogen Agents in Metastatic HSPC

December 20th 2021

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Dr. Ciombor on the Utilization of Maintenance Panitumumab in RAS Wild-Type Metastatic CRC

December 20th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

Dr. Hubbard on the Design of the NRG-GI005 Trial in Colorectal Cancer

December 17th 2021

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

December 17th 2021

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian Cancer

December 17th 2021

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

December 17th 2021

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple Myeloma

December 17th 2021

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Dr. Daver on the Next Steps for Menin Inhibitors in AML

December 17th 2021

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast Cancer

December 16th 2021

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Dr. Bestvina on the Emerging Role of Neoadjuvant Chemoimmunotherapy in Lung Cancer

December 16th 2021

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

Dr. Mark on Establishing MRD as a Surrogate Marker for Survival in Multiple Myeloma

December 16th 2021

Tomer Mark, MD, discusses establishing minimal residual disease (MRD) as a surrogate marker for survival in multiple myeloma.

Dr. Aggarwal the Significance of the IMpower010 Trial in PD-L1+ NSCLC

December 15th 2021

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Dr. Weber Discusses Unmet Needs in Ocular and Mucosal Melanoma

December 15th 2021

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

December 15th 2021

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.